Technical Analysis for RNAC - Cartesian Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Flat | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | -1.13% | |
| MACD Bullish Signal Line Cross | Bullish | -1.13% | |
| Pocket Pivot | Bullish Swing Setup | -1.13% | |
| Wide Bands | Range Expansion | -1.13% | |
| Up 3 Days in a Row | Strength | -1.13% | |
| Upper Bollinger Band Touch | Strength | -1.13% | |
| 20 DMA Support | Bullish | 6.46% | |
| Pocket Pivot | Bullish Swing Setup | 6.46% | |
| Wide Bands | Range Expansion | 6.46% | |
| Crossed Above 20 DMA | Bullish | 22.84% |
| Alert | Time |
|---|---|
| Fell Below 200 DMA | 3 minutes ago |
| Down 1% | 3 minutes ago |
| 1.5x Volume Pace | about 20 hours ago |
| Possible Pocket Pivot | about 20 hours ago |
| 200 DMA Resistance | about 21 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/14/2024
Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company’s lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis, with additional Phase 2 studies planned in systemic lupus erythematosus as well as ocular autoimmune and vasculitic autoimmune basket trials. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.6 |
| 52 Week Low | 11.665 |
| Average Volume | 81,741 |
| 200-Day Moving Average | 26.35 |
| 50-Day Moving Average | 19.71 |
| 20-Day Moving Average | 22.08 |
| 10-Day Moving Average | 23.81 |
| Average True Range | 2.28 |
| RSI (14) | 71.01 |
| ADX | 32.58 |
| +DI | 36.07 |
| -DI | 15.17 |
| Chandelier Exit (Long, 3 ATRs) | 20.61 |
| Chandelier Exit (Short, 3 ATRs) | 23.73 |
| Upper Bollinger Bands | 27.08 |
| Lower Bollinger Band | 17.07 |
| Percent B (%b) | 0.96 |
| BandWidth | 45.32 |
| MACD Line | 1.40 |
| MACD Signal Line | 1.21 |
| MACD Histogram | 0.1883 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.40 | ||||
| Resistance 3 (R3) | 30.25 | 28.84 | 29.78 | ||
| Resistance 2 (R2) | 28.84 | 27.89 | 28.92 | 29.57 | |
| Resistance 1 (R1) | 27.75 | 27.30 | 28.30 | 27.90 | 29.36 |
| Pivot Point | 26.34 | 26.34 | 26.62 | 26.42 | 26.34 |
| Support 1 (S1) | 25.25 | 25.39 | 25.80 | 25.40 | 23.94 |
| Support 2 (S2) | 23.84 | 24.80 | 23.92 | 23.73 | |
| Support 3 (S3) | 22.75 | 23.84 | 23.53 | ||
| Support 4 (S4) | 22.90 |
